The rational design of ARUK2007145, a dual inhibitor of the α and γ isoforms of the lipid kinase phosphatidylinositol 5-phosphate 4-kinase (PI5P4K)†
Gregory G.
Aldred, 
‡a
Timothy P. C.
Rooney,
‡a
Henriette M. G.
Willems,
a
Helen K.
Boffey,
a
Christopher
Green,
§a
John
Skidmore,
a
Jonathan H.
Clarke
a
and
Stephen P.
Andrews
*a
‡a
Timothy P. C.
Rooney,
‡a
Henriette M. G.
Willems,
a
Helen K.
Boffey,
a
Christopher
Green,
§a
John
Skidmore,
a
Jonathan H.
Clarke
a
and
Stephen P.
Andrews
*a
Abstract
The phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are therapeutic targets for diseases such as cancer, neurodegeneration and immunological disorders as they are key components in regulating cell signalling pathways. In an effort to make probe molecules available for further exploring these targets, we have previously reported PI5P4Kα-selective and PI5P4Kγ-selective ligands. Herein we report the rational design of PI5P4Kα/γ dual inhibitors, using knowledge gained during the development of selective inhibitors for these proteins. ARUK2007145 (39) is disclosed as a potent, cell-active probe molecule with ADMET properties amenable to conducting experiments in cells.
Please wait while we load your content...
